MIGS | Ophthalmology Innovation Source

Ivantis

The Hydrus Microstent dilates and scaffolds Schlemm’s canal. More than 2,000 people in 21 countries have been treated with the Hydrus, and recruitment for the company’s U.S. pivotal trial is now complete (n=558). When in place, the device creates a cross-sectional stent that increases the cross-sectional diameter of Schlemm’s canal by “about 4-5 times,” Van…

Transcend Medical

The CyPass Micro-Stent has been implanted in more than 1,000 patients over the course of 10 years as part of multiple clinical trials, and Transcend expects to submit to the FDA during 3Q 2105. The device already has the CE Mark, and two post-marketing European studies are ongoing. The CyPass creates a controlled outflow pathway…

Spotlight on MIGS

Participants: Eric Donnenfeld, MD Eric Donnenfeld, MD is a founding partner of Ophthalmic Consultants of Long Island, Professor of Ophthalmology NYU and a Trustee at Dartmouth Medical School. View Full Profile Richard Lewis, MD Richard A. Lewis, M.D. is the former director of glaucoma at the University of California, Davis before co-founding Sacramento Eye Consultants.…

MicroOptx

The company’s BG implant shunts aqueous to the tear film without risk of internal infection, and has developed a successful prototype with both bench and animal data. The device is miniscule—about 1/100 the size of the most commonly implanted glaucoma device. The nanotechnology’s bands are also about 1/3 the size of the smallest bacteria, providing…

Transcend Medical Ready To Make Move In MIGs

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 042″] Transcend Medical CMO Sean Ianchulev provides an update on COMPASS trial and shares company’s plan for the FDA. Podcast Guest Sean Ianchulev, MD, MPH Dr. Ianchulev is a physician-executive, innovator and venture capital investor with deep life-science and medical technology expertise. As an innovator he has been at the core…

OIS Overview: Haimovitch, Lachman Share Insights On OIS, MIGs, IOLs, etc

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 040″] Veteran Ophthalmology Scribes Larry Haimovitch of Haimovitch Medical Technology Consultants and Mike Lachman of EyeQ Research put down the pens and pick up the Mics to share their insights on ophthalmology.

CEO Russ Trenary Discusses InnFocus’ Push Into The Competitive MIGs Market

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 027″] Ophthalmology industry Veteran Russ Trenary reveals how InnFocus intends to capture a piece of the growing MIGs market. Podcast Guest Russell Trenary Russ Trenary is President & CEO for InnFocus, Inc., an early stage company pioneering a microsurgical solution for glaucoma. He has led, or been a named officer, for…

InnFocus

InnFocus Inc.’s MicroShunt glaucoma drainage implant is designed to reduce intraocular pressure in glaucoma patients. President and CEO Russell Trenary explained that the implant is made from a revolutionary and highly biocompatible material that is ultra-stable and does not degrade. In the past year, InnFocus has been conducting the first randomized controlled study against trabeculectomy,…

FDA Division Directors Detail How Agency Adapts to Innovation

The rush of innovation in ophthalmology – both in drugs and devices – is driving the Food and Drug Administration to adopt guidelines and standards to help expedite approvals. Two key players within the agency, Dr. Wiley Chambers and Dr. Malvina Eydelman, sat down for an open Q&A with Emmett Cunningham, MD, co-chair of OIS@AAO.…

2013 Ophthalmology Innovation Summit Innovator Awards

William J. Link PhD, Managing Director for Versant Ventures, announces the winners of the 2013 OIS Innovator Award. Describing the caliber and achievement that merits this award, Bill recognizes Thomas Burns, President & CEO for Glaukos, and Richard Hill MD, Co-Founder for Glaukos, for their high impact ophthalmic innovations that have successfully improved the lives…

More Value to Ophthalmic Innovators Working with Strategic Investors

Evan Norton of Abbott Ventures sees a trend in which corporate investors are moving up their game to an earlier development stage, which could result in more funding opportunities for innovators. “As a strategic investor, we don’t invest in things unless we see a path for them to be acquired by Abbott. We do, however,…

OIS@ASCRS 2013 Executive Summary – Eye on Innovation

The Second Annual OIS@ASCRS – Ophthalmology Innovation Summit at the American Society of Cataract and Refractive Surgery was held in San Francisco on April 18, 2013. The conference attracted 325 attendees from 29 US states and 21 countries. The purpose of OIS is to create an ecosystem of clinical, technology and business. Uniting this diverse…